PROBLEM TO BE SOLVED: To provide a method for treating an S1P1 receptor-related condition. About 1.5 to about 2.5 mg of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)). Benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) in an amount equivalent to Compound 1 or a pharmaceutically acceptable salt, hydrate or Provided is a method of treating sphingosine 1-phosphate subtype 1 (S1P 1 ) receptor-related disorders, comprising formulating and/or administering a standard dose of a solvate to an individual in need thereof, eg lymphocyte mediated Disease or disorder, autoimmune disease or disorder, inflammatory disease or disorder, ankylosing spondylitis, biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, graft rejection, multiple sclerosis, systemic Lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type I diabetes, hypertensive nephropathy, glomerulosclerosis, myocardial ischemia reperfusion injury and acne. [Selection diagram] Figure 1A【課題】Ｓ１Ｐ１受容体関連状態の処置方法を提供すること【解決手段】約１．５～約２．５ｍｇの（Ｒ）－２－（７－（４－シクロペンチル－３－（トリフルオロメチル）ベンジルオキシ）－１，２，３，４－テトラヒドロシクロペンタ［ｂ］インドール－３－イル）酢酸（化合物１）と同等の量の化合物１又は薬学的に許容されるその塩、水和物又は溶媒和物の標準用量のそれを必要とする個体への処方及び／又は投与を含むスフィンゴシン１－ホスフェートサブタイプ１（Ｓ１Ｐ１）受容体関連障害の処置方法が提供され、例えばリンパ球に媒介される疾患又は障害、自己免疫疾患又は障害、炎症性疾患又は障害、強直性脊椎炎、胆汁性肝硬変、癌、乾癬、乾癬性関節炎、関節リウマチ、クローン病、移植片拒絶、多発性硬化症、全身性エリテマトーデス、炎症性腸疾患、潰瘍性大腸炎、Ｉ型糖尿病、高血圧性腎症、糸球体硬化症、心筋虚血再灌流傷害及びざ瘡である。【選択図】図１Ａ
